Observational Study of the A&M Breathalyzer PROTECT Kiosk for COVID-19 Detection

This study is testing a new device called the A&M Breathalyzer PROTECT Kiosk. This device aims to passively detect COVID-19 by analyzing your breath. Researchers want to make sure the kiosk works well and can be used in different settings, especially for military personnel. You can join if you are between 18 and 89 years old, whether you have COVID-19 symptoms or not, and are already getting screened for COVID-19, Flu, or RSV at Brooke Army Medical Center (BAMC). The main goals are to optimize how the kiosk works and evaluate its breath capture system. This is an observational study, meaning researchers are watching and collecting information, not giving a new treatment. The study is planned to enroll 100 participants.

Study design
This is an observational study with no specified phase, aiming to enroll 100 participants. Researchers will collect breath readings from participants using the A&M Breathalyzer PROTECT Kiosk.
What's involved
You would provide breath samples using the A&M Breathalyzer PROTECT Kiosk. The study will run from enrollment through to study completion, which could be a minimum of 48 hours up to 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment through to study completion, which could be a minimum of 48 hours up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06402318

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

Recruiting
Not specifiedAges 18–89Observational
The Geneva Foundation
~100 participants
Updated 2025-12-10 on ClinicalTrials.gov
What's tested:A&M Breathalyzer PROTECT Kiosk

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Concentration on optimization and operationalizing the A&M Breathalyzer PROTECT Kiosk
Measured over Enrollment through to study completion (min 48hrs through to 12 months)
+1 more outcome measured
COVID-19
SARS CoV 2 Virus
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Respiratory Distress Syndrome
1 sites across 1 states
Texas1
  • Tony Yuan, PhD · PRINCIPAL_INVESTIGATOR · Uniformed Services University of the Health Sciences (USUHS)
  • Michael Morris, MD · PRINCIPAL_INVESTIGATOR · Brooke Army Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Asymptomatic and symptomatic individuals 18 years and older
Receiving standard COVID-19, Flu and/or RSV screening and testing at BAMC
Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened
Ability to understand consent

Exclusion

Any individual under age of 18
Anyone unable to comply (or be assisted) with study procedures
Anyone not able to provide temperature thermal scan, and/or perform exhaled breath for approximately 8 seconds
  • Concentration on optimization and operationalizing the A&M Breathalyzer PROTECT KioskEnrollment through to study completion (min 48hrs through to 12 months)

    Optimization and operationalize the A\&M Breathalyzer PROTECT Kiosk, to test its detection capabilities of COVID-19, Flu, and/or RSV among symptomatic and asymptomatic COVID-19, Flu or RSV carrier vs. those not infected compared to gold standard RT-PCR.

  • Concentration on evaluating the passive sensing, breath capture system built within the A&M Breathalyzer PROTECT Kiosk.Enrollment through to study completion (min 48hrs through to 12 months)

    This evaluation would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.